Neuroblastoma

Indexed in Crossref

12 abstracts matching neuroblastoma from the meeting's journal supplement, fetched live from Crossref 2026-11-12 10:49 UTC. This is a keyword search, not the complete abstract book.

• 10007
  Characteristics and survival of 4N and non-4N metastatic neuroblastoma across treatment eras: A report from the International Neuroblastoma Risk Group Task Force.

  Michael Mitchell, Yingchao Yuan, Arlene Naranjo, Ruth Lydia Ladenstein et al.
• 3116
  Efficacy of targeting replication stress in neuroblastoma.

  Carla Sofia Sampaio, Eric Wu, Richard Kolodner, Jean Yin Jen Wang et al.
• E15125
  Evaluating the efficacy and mechanisms of action of seriniquinone against pediatric neuroblastoma.

  Peter E. Zage, Sriprada Kattamuri, Erin Yamaoka, Disha Surana et al.
• 10043
  Utilization and outcomes of minimally invasive resection in patients with neuroblastoma and Wilms tumor in a national cohort.

  Courtney N. Day, Elizabeth B. Habermann, Stephanie F. Polites
• 10040
  Changes in the incidence of second malignant neoplasms in neuroblastoma over time: An updated SEER database analysis.

  Arhanti Sadanand, Michael Dang, Tara O. Henderson, Lisa Diller et al.
• 10037
  Dinutuximab beta in combination with chemotherapy in patients with refractory or relapsed neuroblastoma: A national prospective study (2020/ABM/01/00055).

  Aleksandra Wieczorek, Urszula Zebrowska, Gabriela Mielecka-Jarmocik, Agnieszka Pac et al.
• 10038
  A study of the safety, efficacy, and pharmacokinetics of SPJ-101CA as maintenance therapy for newly diagnosed high-risk neuroblastoma.

  Atsushi Makimoto, Hiroyuki Fujisaki, Yoshiyuki Takahashi, Kimikazu Matsumoto et al.
• 10033
  Association of response with survival in patients with relapsed/refractory high-risk neuroblastoma: A report from NANT Consortium.

  Michael Migotsky, Judith Villablanca, Yueh-Yun Chi, Erica Ma et al.
• TPS10058
  Feasibility study of prolonged administration of naxitamab, irinotecan, and temozolomide for patients with relapsed or refractory neuroblastoma.

  Samantha Martin, Emily Blair, Sarah Sexton, Ketki Bhushan et al.
• 10044
  Impact of central review process on response rates in neuroblastoma clinical trials: A report from NANT Consortium.

  Michael Migotsky, Judith Villablanca, Yueh-Yun Chi, Anahit Baregamyan et al.
• 10013
  RAPID: A pilot feasibility study of rapid dinutuximab infusion in patients with relapsed/refractory (RR) high-risk neuroblastoma (HRNBL).

  Sara-Jane N. Onyeama, Mariel Trunzo, Yueh-Yun Chi, Anahit Baregamyan et al.
• 10028
  Clinical impact of panel-based next-generation sequencing in a real-world cohort of neuroblastoma patients.

  Samantha Martin, Holly Janelle Roberts, Lorena Lazo de la Vega, Yvonne Y. Li et al.